{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,4]],"date-time":"2026-07-04T13:42:47Z","timestamp":1783172567813,"version":"3.54.6"},"reference-count":35,"publisher":"Wiley","issue":"9","license":[{"start":{"date-parts":[[2020,8,16]],"date-time":"2020-08-16T00:00:00Z","timestamp":1597536000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"name":"Novartis Pharma AG, Basel, Switzerland."}],"content-domain":{"domain":["headachejournal.onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Headache"],"published-print":{"date-parts":[[2020,10]]},"abstract":"<jats:sec>\n                    <jats:title>Objective<\/jats:title>\n                    <jats:p>To assess the impact of a migraine management program offered as a complimentary service by a company within its corporate well\u2010being program.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Migraine imposes a substantial burden on patients, families, employers, and societies. As migraine primarily affects working\u2010age adults, this has important implications for both employees and employers. Workplace educational and well\u2010being programs positively contribute to employees\u2019 productivity, reduce costs related to absenteeism, and improve the quality of life of the employees living with migraine.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>This was a non\u2010interventional cohort study, which followed employees and their family members over time. Participants received 1 telemedicine consultation to determine migraine diagnosis or a high probability of having migraine and 6 sessions of individualized telecoaching from a specialized nurse via a specially developed smartphone application to optimize their migraine management leveraging all appropriate medical and lifestyle options. Participants were evaluated during the program and at 3\u00a0months after completion through a series of validated questionnaires including Migraine Disability Assessment (MIDAS), Patient Activation Measure (PAM), and satisfaction with the services offered. A cost analysis was also performed to determine the economic benefit of the program considering the number of completers, dropouts, their associated program costs, MIDAS data, average salary of a Swiss employee in the pharma sector, and working days per year.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      Of the 141 participants enrolled in the program, 79 completed 6\u2010month and 42 completed 9\u2010month assessments. The total MIDAS scores (mean, standard deviation [SD]) significantly improved from baseline by 54% at Month 6 (15.0 [13.6] vs 6.9 [8.2]; mean [SD] reduction: 8.1 [12.9], 95% confidence interval [CI]: 5.6\u201010.6;\n                      <jats:italic>P<\/jats:italic>\n                      \u00a0&lt;\u00a0.0001) and by 64% at Month 9 (15.4 [14.7] vs 5.6 [6.0]; mean [SD] reduction: 9.8 [14.0], 95% CI: 6.6\u201013.0;\n                      <jats:italic>P<\/jats:italic>\n                      \u00a0&lt;\u00a0.0001). The PAM scores also significantly improved from baseline by 8% at Month 6 (63.8 [10.9] vs 69.6 [12.8]; mean [SD] increase: 5.8 [12.8], 95% CI: 3.2\u20108.4;\n                      <jats:italic>P<\/jats:italic>\n                      \u00a0=\u00a0.003) and 11% at Month 9 (63.5 [10.7] vs 71.3 [12.2]; mean [SD] increase: 7.8 [11.0], 95% CI: 4.3\u201011.2;\n                      <jats:italic>P<\/jats:italic>\n                      \u00a0=\u00a0.003). At Month 6, common coaching lessons and respective action plans focused on progressive muscle relaxation, sleep, hydration, nutrition, general disease education, and stress management. The exit survey showed that the majority of the participants who completed the program had a meaningful and sustained improvement in their overall health and reported a high level of satisfaction with the program. The cost analysis revealed that on average participants gained 10.8 (95% CI: 9.3\u201012.3) working days\/year that were previously lost due to migraine, resulting in a positive return on investment (ROI) of 490% (95% CI: 410%\u2010570%), indicating a higher magnitude of savings that could be achieved by the implementation of such program. In addition to ROI and work productivity gained, participants also gained on average 13.6 (95% CI: 9.9\u201017.3) migraine\u2010free days\/year for their private and social life.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>The employer\u2010sponsored disease management program provided a better understanding of migraine, promoted methods and approaches to improve management by combining medical and lifestyle options leading to significant improvements in migraine symptoms that sustained beyond the intervention, supporting prolonged effectiveness of such programs. The program also provided a high ROI to the employer, supporting that the systematic inclusion of such programs into corporate well\u2010being initiatives can be of significant benefit not only to the impacted individuals but to the employers as well.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1111\/head.13933","type":"journal-article","created":{"date-parts":[[2020,8,16]],"date-time":"2020-08-16T10:39:52Z","timestamp":1597574392000},"page":"1947-1960","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":23,"title":["Employee and Employer Benefits From a Migraine Management Program: Disease Outcomes and Cost Analysis"],"prefix":"10.1111","volume":"60","author":[{"given":"Leonhard","family":"Schaetz","sequence":"first","affiliation":[{"name":"Novartis Pharma AG Basel Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Timo","family":"Rimner","sequence":"additional","affiliation":[{"name":"Medgate Basel Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Purnima","family":"Pathak","sequence":"additional","affiliation":[{"name":"Novartis Ireland Ltd Dublin Ireland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Juanzhi","family":"Fang","sequence":"additional","affiliation":[{"name":"Novartis Pharmaceuticals Corporation East Hanover NJ USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Deepak","family":"Chandrasekhar","sequence":"additional","affiliation":[{"name":"Healint Pte Ltd. Singapore Singapore"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jelena","family":"Mueller","sequence":"additional","affiliation":[{"name":"Novartis Pharma AG Basel Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter S.","family":"Sandor","sequence":"additional","affiliation":[{"name":"Neurology &amp; Neurorehabilitation RehaClinic Bad Zurzach Switzerland"},{"name":"Department of Neurology University Hospital Zurich Z\u00fcrich Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andreas R.","family":"Gantenbein","sequence":"additional","affiliation":[{"name":"Neurology &amp; Neurorehabilitation RehaClinic Bad Zurzach Switzerland"},{"name":"Department of Neurology University Hospital Zurich Z\u00fcrich Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2020,8,16]]},"reference":[{"key":"e_1_2_7_2_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1474-4422(18)30322-3"},{"key":"e_1_2_7_3_1","doi-asserted-by":"publisher","DOI":"10.1111\/head.13202"},{"key":"e_1_2_7_4_1","doi-asserted-by":"publisher","DOI":"10.1186\/s10194-018-0839-1"},{"key":"e_1_2_7_5_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1474-4422(16)30293-9"},{"key":"e_1_2_7_6_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1468-1331.2006.01184.x"},{"key":"e_1_2_7_7_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1468-1331.2011.03612.x"},{"key":"e_1_2_7_8_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1468-1331.2011.03590.x"},{"key":"e_1_2_7_9_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40120-018-0113-0"},{"key":"e_1_2_7_10_1","first-page":"232","article-title":"Evaluating the impact of migraine on work productivity in Switzerland using self\u2010reported data using the Migraine\u2010Buddy\u00a9 application","volume":"25","author":"Paris N","year":"2018","journal-title":"Eur J Neurol"},{"key":"e_1_2_7_11_1","doi-asserted-by":"publisher","DOI":"10.1186\/1129-2377-14-29"},{"key":"e_1_2_7_12_1","volume-title":"Migraine\u2019s impact on employment in Europe","author":"The Work Foundation"},{"key":"e_1_2_7_13_1","doi-asserted-by":"publisher","DOI":"10.1136\/jnnp.2009.192492"},{"key":"e_1_2_7_14_1","doi-asserted-by":"publisher","DOI":"10.1093\/asjof\/ojz007"},{"key":"e_1_2_7_15_1","doi-asserted-by":"publisher","DOI":"10.1097\/JOM.0000000000000781"},{"key":"e_1_2_7_16_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ctcp.2019.04.001"},{"key":"e_1_2_7_17_1","first-page":"156","article-title":"An evaluation of the impact of educational programming on employee\u2010disability","volume":"14","author":"Landy S","year":"2003","journal-title":"Headache Pain"},{"key":"e_1_2_7_18_1","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.53.4.868"},{"key":"e_1_2_7_19_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1468-2982.2008.01551.x"},{"key":"e_1_2_7_20_1","doi-asserted-by":"publisher","DOI":"10.1097\/JOM.0b013e318192bcd1"},{"key":"e_1_2_7_21_1","doi-asserted-by":"publisher","DOI":"10.1185\/030079904X10151"},{"key":"e_1_2_7_22_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jval.2020.04.931"},{"issue":"1","key":"e_1_2_7_23_1","first-page":"306","article-title":"Impact of an employer\u2010provided migraine coaching program on patient burden and engagement","volume":"27","author":"Schaetz L","year":"2020","journal-title":"Eur J Neurol"},{"key":"e_1_2_7_24_1","article-title":"Impact of an employer\u2010provided migraine coaching program on burden and patient engagement: Results from interim analysis","volume":"39","author":"Schaetz L","year":"2019","journal-title":"Cephalalgia"},{"key":"e_1_2_7_25_1","doi-asserted-by":"crossref","DOI":"10.1212\/WNL.94.15_supplement.1126","article-title":"Impact of an employer\u2010provided migraine coaching program on burden and patient engagement: Results from interim analysis","volume":"94","author":"Schaetz L","year":"2020","journal-title":"Neurology"},{"key":"e_1_2_7_26_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijsu.2014.07.014"},{"key":"e_1_2_7_27_1","doi-asserted-by":"publisher","DOI":"10.1212\/01.WNL.0000078940.53438.83"},{"key":"e_1_2_7_28_1","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0000000000006697"},{"key":"e_1_2_7_29_1","first-page":"S550","article-title":"Clinical clues and clinical rules: Primary vs secondary headache","volume":"3","author":"Dodick DW","year":"2003","journal-title":"Adv Stud Med"},{"key":"e_1_2_7_30_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0304-3959(00)00305-5"},{"key":"e_1_2_7_31_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1475-6773.2005.00438.x"},{"key":"e_1_2_7_32_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jmpt.2003.11.003"},{"key":"e_1_2_7_33_1","doi-asserted-by":"publisher","DOI":"10.1109\/MS.2004.1293068"},{"key":"e_1_2_7_34_1","volume-title":"Wages, Income From Employment and Labour Costs","author":"Federal Statistical Office","year":"2018"},{"key":"e_1_2_7_35_1","volume-title":"Wages, Income From Employment and Labour Costs","author":"Federal Statistical Office","year":"2018"},{"key":"e_1_2_7_36_1","article-title":"How much change in headache\u2010related disability is clinically meaningful? Estimating minimally important difference (MID) or change in MIDAS using data from the AMPP study","volume":"57","author":"Lipton RB","year":"2017","journal-title":"Headache"}],"container-title":["Headache: The Journal of Head and Face Pain"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fhead.13933","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/head.13933","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1111\/head.13933","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/headachejournal.onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/head.13933","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,11,2]],"date-time":"2025-11-02T10:49:29Z","timestamp":1762080569000},"score":1,"resource":{"primary":{"URL":"https:\/\/headachejournal.onlinelibrary.wiley.com\/doi\/10.1111\/head.13933"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,8,16]]},"references-count":35,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2020,10]]}},"alternative-id":["10.1111\/head.13933"],"URL":"https:\/\/doi.org\/10.1111\/head.13933","archive":["Portico"],"relation":{},"ISSN":["0017-8748","1526-4610"],"issn-type":[{"value":"0017-8748","type":"print"},{"value":"1526-4610","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,8,16]]},"assertion":[{"value":"2020-04-09","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2020-07-06","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2020-08-16","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}